Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments
- 123 Downloads
To develop a new tool to assess constraints due to urinary treatments in neurological patients.
Materials and methods
A prospective, monocentric study has been conducted from January to May 2017. Out-patients (multiple sclerosis, spinal cord injury, Parkinson disease) were included in a referral center if they had LUTS treatment for at least 3 months. To validate psychometric properties, we conducted a literature review, qualitative interviews, and discussion with a panel of six experts. Comprehension, acceptation, and pertinence were tested by a pilot study. A validation study, designed to calculate content validity, internal consistency reliability, and test–retest reliability [intraclass correlation coefficient (ICC)] has been conducted. The primary outcome was good psychometric properties defined with Cronbach’s α > 0.7 and ICC > 0.7.
Comprehension, acceptation, and pertinence were excellent. Validation study showed a perfect content validity (r2 = 1) and excellent internal consistency reliability (Cronbach’ α = 0.90). Total score was between 0 (best score) to 66 (maximal constraints). Test–retest reliability calculated using ICC was 0.81. Time to fill questionnaire was 4 min 20 s. The final version was composed by 22 items.
LUTS TCA is the first validated tool to assess constraints of urinary treatment and has excellent psychometric properties.
KeywordsConstraints Neurogenic bladder Questionnaire Urinary treatment evaluation Tool
Lower urinary tract symptom
Clean intermittent self-catheterization
Intraclass correlation coefficient
Treatment Satisfaction Questionnaire for Medication
Treatment Satisfaction with Medicines Questionnaire
International Prostate Symptoms Score
Patient global impression of improvement
Overactive Bladder Symptom Score
The authors thank SIFUD PP (Société Interdisciplinaire Francophone d’UroDynamique et de Pelvi Périnéologie) and GREEN-Lilial for their financial support.
Dr. Turmel: protocol/project development/data collection or management/data analysis/manuscript writing/editing. Pr. Levy: data analysis/manuscript writing/editing. Dr. Hentzen: protocol/project development/data collection or management. Dr. Chesnel: protocol/project development/data collection or management. Dr. Charlanes: protocol/project development/data collection or management. Dr. Sheikh-ismael: protocol/project development/data collection or management/manuscript writing/editing. Pr. Amarenco: protocol/project development/data collection or management/data analysis/manuscript writing/editing. Dr. Manceau: protocol/project development/manuscript writing/editing.
Compliance with ethical standards
Conflict of interest
No conflict of interest.
- 5.Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR (2012) Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol 61(1):88–95 (Epub 26 July 2011) CrossRefPubMedGoogle Scholar
- 8.Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E et al (2014) Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 65(4):755–65. https://doi.org/10.1016/j.eururo.2013.11.010 (Epub 1 Nov 2013, review) CrossRefPubMedGoogle Scholar
- 9.Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET et al (2016) Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 35(2):246–51 (Epub 24 Dec 2014) CrossRefPubMedGoogle Scholar
- 11.Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418–25. https://doi.org/10.1016/j.eururo.2014.11.006 (Epub 20 Nov 2014) CrossRefPubMedGoogle Scholar
- 17.Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53(2):275–287 (Epub 16 Oct 2007)Google Scholar